Myasthenia gravis-like Myopathy in metastatic cutaneous Squamous Cell Carcinoma under Anti-PD-1 Therapy

被引：0
|
作者：
Koett, J. [1 ]
Christolouka, M. [1 ]
Haalck, T. [1 ]
Schneider, S. W. [1 ]
Gebhardt, C. [1 ]
机构：
[1] Univ Hamburg Eppendorf, Dermatol & Venerol, Hamburg, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2020年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P113
引用
收藏
页码：75 / 75
页数：1
相关论文
共 50 条
  • [1] Metastatic Merkel Cell-Carcinoma and Myasthenia gravis: A Contraindication for Anti- PD-1 Antibody Therapy?
    Hoge, J.
    Hagenacker, T.
    Chorti, E.
    Jockenhoefer, F.
    Zaremba, A.
    Ugurel, S.
    Schadendorf, D.
    Roesch, A.
    Livingstone, E.
    Zimmer, L.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 28 - 28
  • [2] Therapy of the metastatic Merkel Cell Carcinoma with the Anti-PD-1 Antibody Pembrolizumab
    Meier, K.
    Wilhelmi, J.
    Lomberg, D.
    Spaenkuch, I
    Scheu, A.
    Leiter, U.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 171 - 171
  • [3] Response to Anti-PD-1 Therapy in Metastatic Merkel Cell Carcinoma Metastatic to the Heart and Pancreas
    Mantripragada, Kalyan
    Birnbaum, Ariel
    CUREUS, 2015, 7 (12):
  • [4] Successful management of in-transit cutaneous squamous cell carcinoma with anti-PD-1 immunotherapy
    Furkert, Chris
    Martin, Richard
    Sharma, Avinash
    Rivalland, Gareth
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [5] Successful management of in-transit cutaneous squamous cell carcinoma with anti-PD-1 immunotherapy
    Chris Furkert
    Richard Martin
    Avinash Sharma
    Gareth Rivalland
    World Journal of Surgical Oncology, 21
  • [6] Anti-PD-1 therapy using cemiplimab for advanced cutaneous squamous cell carcinoma in HIV patient: A case report
    Alloghbi, Abdurahman
    Ninia, James
    Alshare, Bayan
    Hotaling, Jeffrey
    Raza, Syed
    Sukari, Ammar
    CLINICAL CASE REPORTS, 2021, 9 (12):
  • [7] Advanced Squamous Cell Carcinoma: Complete Remission to Anti-PD-1 Antibody Therapy
    Gellrich, F. F.
    Beissert, S.
    Meier, F.
    AKTUELLE DERMATOLOGIE, 2019, 45 (05) : 233 - 235
  • [8] Anti-PD-1 Therapy is Beneficial for the Survival of Patients with Oral Squamous Cell Carcinoma
    Feng, Liang
    Yin, Ke
    Zhang, Suxin
    Chen, Zhong
    Bao, Yang
    Li, Tianke
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2723 - 2731
  • [9] Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    Saada-Bouzid, E.
    Defaucheux, C.
    Karabajakian, A.
    Coloma, V. P.
    Servois, V.
    Paoletti, X.
    Even, C.
    Fayette, J.
    Guigay, J.
    Loirat, D.
    Peyrade, F.
    Alt, M.
    Gal, J.
    Le Tourneau, C.
    ANNALS OF ONCOLOGY, 2017, 28 (07) : 1605 - 1611
  • [10] Carboplatin and paclitaxel after anti-PD-1 or anti-PD-L1 antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck
    Humphries, Audrey
    Zhou, Connie J.
    Welsh, Madeleine
    Lem, Melinda
    Kang, Hyunseok
    Algazi, Alain P.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2024, 46 (02): : 321 - 327
12345